Karin F.K. Ejendal
Purdue University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karin F.K. Ejendal.
PLOS Neglected Tropical Diseases | 2012
Jason M. Meyer; Karin F.K. Ejendal; Larisa V. Avramova; Elisabeth Garland-Kuntz; Gloria I. Giraldo-Calderón; Tarsis F. Brust; Val J. Watts; Catherine A. Hill
Background Many neglected tropical infectious diseases affecting humans are transmitted by arthropods such as mosquitoes and ticks. New mode-of-action chemistries are urgently sought to enhance vector management practices in countries where arthropod-borne diseases are endemic, especially where vector populations have acquired widespread resistance to insecticides. Methodology/Principal Findings We describe a “genome-to-lead” approach for insecticide discovery that incorporates the first reported chemical screen of a G protein-coupled receptor (GPCR) mined from a mosquito genome. A combination of molecular and pharmacological studies was used to functionally characterize two dopamine receptors (AaDOP1 and AaDOP2) from the yellow fever mosquito, Aedes aegypti. Sequence analyses indicated that these receptors are orthologous to arthropod D1-like (Gαs-coupled) receptors, but share less than 55% amino acid identity in conserved domains with mammalian dopamine receptors. Heterologous expression of AaDOP1 and AaDOP2 in HEK293 cells revealed dose-dependent responses to dopamine (EC50: AaDOP1 = 3.1±1.1 nM; AaDOP2 = 240±16 nM). Interestingly, only AaDOP1 exhibited sensitivity to epinephrine (EC50 = 5.8±1.5 nM) and norepinephrine (EC50 = 760±180 nM), while neither receptor was activated by other biogenic amines tested. Differential responses were observed between these receptors regarding their sensitivity to dopamine agonists and antagonists, level of maximal stimulation, and constitutive activity. Subsequently, a chemical library screen was implemented to discover lead chemistries active at AaDOP2. Fifty-one compounds were identified as “hits,” and follow-up validation assays confirmed the antagonistic effect of selected compounds at AaDOP2. In vitro comparison studies between AaDOP2 and the human D1 dopamine receptor (hD1) revealed markedly different pharmacological profiles and identified amitriptyline and doxepin as AaDOP2-selective compounds. In subsequent Ae. aegypti larval bioassays, significant mortality was observed for amitriptyline (93%) and doxepin (72%), confirming these chemistries as “leads” for insecticide discovery. Conclusions/Significance This research provides a “proof-of-concept” for a novel approach toward insecticide discovery, in which genome sequence data are utilized for functional characterization and chemical compound screening of GPCRs. We provide a pipeline useful for future prioritization, pharmacological characterization, and expanded chemical screening of additional GPCRs in disease-vector arthropods. The differential molecular and pharmacological properties of the mosquito dopamine receptors highlight the potential for the identification of target-specific chemistries for vector-borne disease management, and we report the first study to identify dopamine receptor antagonists with in vivo toxicity toward mosquitoes.
Protein Science | 2006
Karin F.K. Ejendal; Ndeye Khady Diop; Linda C. Schweiger; Christine A. Hrycyna
Several members of the ATP‐binding cassette (ABC) transporter superfamily, including P‐glycoprotein and the half‐transporter ABCG2, can confer multidrug resistance to cancer cells in culture by functioning as ATP‐dependent efflux pumps. ABCG2 variants harboring a mutation at arginine 482 have been cloned from several drug‐resistant cell lines, and these variants differ in their substrate transport phenotype. In this study, we changed the wild‐type arginine 482 in human ABCG2 to each one of the 19 other standard amino acids and expressed each one transiently in HeLa cells. Using the 5D3 antibody that recognizes a cell surface epitope of ABCG2, we observed that all the mutants were expressed at the cell surface. However, the mutant ABCG2 proteins differed markedly in transport activity. All of the variants were capable of transporting one or more of the substrates used in this study, with the exception of the R482K mutant, which is completely devoid of transport ability. Six of the mutants (R482G, R482H, R482K, R482P, R482T, and R482Y) and the wild‐type protein (R482wt) were selected for studies of basal and stimulated ATPase activity and photoaffinity labeling with the substrate analog [125I]iodoarylazidoprazosin. Whereas these seven ABCG2 variants differed markedly in ATPase activity, all were able to specifically bind the substrate analog [125I]iodoarylazidoprazosin. These data suggest that residue 482 plays an important role in substrate transport and ATP turnover, but that the nature of this amino acid may not be important for substrate recognition and binding.
Molecular and Cellular Endocrinology | 2011
Pierre-Alexandre Vidi; Karin F.K. Ejendal; Julie A. Przybyla; Val J. Watts
G protein-coupled receptor (GPCR) signaling is mediated by protein-protein interactions at multiple levels. The characterization of the corresponding protein complexes is therefore paramount to the basic understanding of GPCR-mediated signal transduction. The number of documented interactions involving GPCRs is rapidly growing, and appreciating the functional significance of these complexes is clearly the next challenge. New experimental approaches including protein complementation assays (PCAs) have recently been used to examine the composition, plasma membrane targeting, and desensitization of protein complexes involved in GPCR signaling. These methods also hold promise for better understanding of drug-induced effects on GPCR interactions. This review focuses on the application of fluorescent PCAs for the study of GPCR signaling. Potential applications of PCAs in high-content screens are also presented. Non-fluorescent PCA techniques as well as combined assays for the detection of ternary and quaternary protein complexes are briefly discussed.
PLOS Neglected Tropical Diseases | 2015
Andrew B. Nuss; Karin F.K. Ejendal; Trevor Doyle; Jason M. Meyer; Emma G. Lang; Val J. Watts; Catherine A. Hill
Background New mode-of-action insecticides are sought to provide continued control of pesticide resistant arthropod vectors of neglected tropical diseases (NTDs). We previously identified antagonists of the AaDOP2 D1-like dopamine receptor (DAR) from the yellow fever mosquito, Aedes aegypti, with toxicity to Ae. aegypti larvae as leads for novel insecticides. To extend DAR-based insecticide discovery, we evaluated the molecular and pharmacological characteristics of an orthologous DAR target, CqDOP2, from Culex quinquefasciatus, the vector of lymphatic filariasis and West Nile virus. Methods/Results CqDOP2 has 94.7% amino acid identity to AaDOP2 and 28.3% identity to the human D1-like DAR, hD1. CqDOP2 and AaDOP2 exhibited similar pharmacological responses to biogenic amines and DAR antagonists in cell-based assays. The antagonists amitriptyline, amperozide, asenapine, chlorpromazine and doxepin were between 35 to 227-fold more selective at inhibiting the response of CqDOP2 and AaDOP2 in comparison to hD1. Antagonists were toxic to both C. quinquefasciatus and Ae. aegypti larvae, with LC50 values ranging from 41 to 208 μM 72 h post-exposure. Orthologous DOP2 receptors identified from the African malaria mosquito, Anopheles gambiae, the sand fly, Phlebotomus papatasi and the tsetse fly, Glossina morsitans, had high sequence similarity to CqDOP2 and AaDOP2. Conclusions DAR antagonists represent a putative new insecticide class with activity against C. quinquefasciatus and Ae. aegypti, the two most important mosquito vectors of NTDs. There has been limited change in the sequence and pharmacological properties of the DOP2 DARs of these species since divergence of the tribes Culicini and Aedini. We identified antagonists selective for mosquito versus human DARs and observed a correlation between DAR pharmacology and the in vivo larval toxicity of antagonists. These data demonstrate that sequence similarity can be predictive of target potential. On this basis, we propose expanded insecticide discovery around orthologous DOP2 targets from additional dipteran vectors.
Journal of Signal Transduction | 2012
Karin F.K. Ejendal; Carmen W. Dessauer; Terence E. Hébert; Val J. Watts
Chronic dopamine receptor activation is implicated in several central nervous system disorders. Although acute activation of Gα i-coupled D2 dopamine receptors inhibits adenylyl cyclase, persistent activation enhances adenylyl cyclase activity, a phenomenon called heterologous sensitization. Previous work revealed a requirement for Gα s in D2-induced heterologous sensitization of AC5. To elucidate the mechanism of Gα s dependency, we expressed Gα s mutants in Gα s-deficient Gnas E2−/E2− cells. Neither Gα s-palmitoylation nor Gα s-Gβγ interactions were required for sensitization of AC5. Moreover, we found that coexpressing βARKct-CD8 or Sar1(H79G) blocked heterologous sensitization. These studies are consistent with a role for Gα s-AC5 interactions in sensitization however, Gβγ appears to have an indirect role in heterologous sensitization of AC5, possibly by promoting proper signalosome assembly.
Methods in Enzymology | 2013
Karin F.K. Ejendal; Jason M. Conley; Chang-Deng Hu; Val J. Watts
Emerging evidence indicates that G protein-coupled receptor (GPCR) signaling is mediated by receptor-receptor interactions at multiple levels. Thus, understanding the biochemistry and pharmacology of those receptor complexes is an important part of delineating the fundamental processes associated with GPCR-mediated signaling in human disease. A variety of experimental approaches have been used to explore these complexes, including bimolecular fluorescence complementation (BiFC) and multicolor BiFC (mBiFC). BiFC approaches have recently been used to explore the composition, cellular localization, and drug modulation of GPCR complexes. The basic methods for applying BiFC and mBiFC to study GPCRs in living cells are the subject of the present chapter.
Plant Journal | 2005
Markus Geisler; Joshua J. Blakeslee; Rodolphe Bouchard; Ok Ran Lee; Vincent Vincenzetti; Anindita Bandyopadhyay; Boosaree Titapiwatanakun; Wendy Ann Peer; Aurélien Bailly; Elizabeth L. Richards; Karin F.K. Ejendal; Aaron P. Smith; Célia Baroux; Ueli Grossniklaus; Axel Müller; Christine A. Hrycyna; Robert Dudler; Angus S. Murphy; Enrico Martinoia
Cancer Research | 2007
Kazumasa Takenaka; Jessica A. Morgan; George L. Scheffer; Masashi Adachi; Clinton F. Stewart; Daxi Sun; Markos Leggas; Karin F.K. Ejendal; Christine A. Hrycyna; John D. Schuetz
Molecular Pharmacology | 2004
Karin F.K. Ejendal; Christine A. Hrycyna
Insect Biochemistry and Molecular Biology | 2011
Jason M. Meyer; Karin F.K. Ejendal; Val J. Watts; Catherine A. Hill